Fluocinonide
Active ingredient · 2 therapeutic classes
Sold as LIDEX · LYDERM · LIDEMOL
- Drug class
- Corticosteroids
- Availability
- Prescription only
- Routes
- Topical
- Markets covered
- 3
- Products on record
- 9
- FDA reports (12 mo)
- 331
Overview
Plain-language summary, compiled from the cited regulatory records
Fluocinonide is a corticosteroid medication [1]. It is approved for the relief of inflammatory and itchy symptoms associated with corticosteroid-responsive skin conditions in individuals aged 12 years and older [1]. This medication is intended for short-term use, with treatment typically not exceeding two consecutive weeks [1]. The total weekly dosage should not exceed 60 grams [1]. It is advised to avoid using fluocinonide on the face, groin, or armpits [1].
In the past 12 months, there have been 331 adverse event reports associated with fluocinonide [2]. Common reactions reported include rash, off-label use, the drug being ineffective, itching (pruritus), and diarrhea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 4 | March 22, 2025 |
| US United States | FDA | 3 | July 3, 2025 |
| GB United Kingdom | MHRA | 2 | September 19, 2025 |
CACanada· Health Canada
4 products
Uses
LYDERM (fluocinonide) is indicated for topical therapy of corticosteroid responsive acute and chronic skin eruptions where an anti-inflammatory, anti-allergenic and anti-pruritic activity in the topical management is required.
How to take
USUnited States· FDA
3 products
Uses
1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older. ( 1 ) Limitation of Use: Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
( 1 ) Avoid use on the face, groin, or axillae. 2 ) Avoid use in perioral dermatitis or rosacea. 4) ]. 1% for longer than 2 weeks has not been established and because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
Therapy should be discontinued when control of the disease is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Do not use more than half of the 120 g tube per week. 1% should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae.
GBUnited Kingdom· MHRA
2 products
Uses
Metosyn is suitable for treating a wide variety of local inflammatory, pruritic and allergic disorders of the skin.
It is indicated in the following conditions:
Eczema and dermatitis: atopic eczema, seborrhoeic dermatitis, discoid eczema, contact dermatitis, neurodermatitis. Prurigo, psoriasis (excluding widespread plaque psoriasis). Lichen planus. Discoid lupus erythematosus. Metosyn Ointment with its emollient effects, is particularly suitable for dry scaly lesions.
How to take
Drug interactions
Known interactions involving Fluocinonide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 00716863 · revised March 22, 2025
- [2]FDA DailyMed · 16c7d142-e695-4e… · revised July 3, 2025 [PDF]
- [3]MHRA (UK) · PL440950015 · revised June 20, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.